

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	Art Unit:
BOCK, et al.	)	Examiner:
Serial No.: 10/574,084	)	Washington, D.C.
Filed: March 30, 2006	)	October 28, 2010
For: A METHOD OF MODULATING	)	Docket No.: BOCK=9
CELL SURVIVAL,	)	
DIFFERENTIATION AND/OR...	)	Confirmation No.: 3782

REQUEST TO CORRECT INVENTORSHIP UNDER 37 CFR 1.48(a)

U.S. Patent and Trademark Office  
Customer Service Window  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

S i r :

Pursuant to 37 CFR 1.48(a), Applicants request to add  
Christina Kasper  
Nørredamsvej 93  
DK-3480 Fredensborg, Denmark  
Citizen: Denmark

Jette Sandholm Jensen Kastrup  
Tokkekøbvej 6, DK-3450 Allerød, Denmark  
Citizen: Denmark

as inventors.

In support of this request, applicants submit

- (1) statements (two) from the omitted inventors
- (2) a declaration executed by the actual inventors (i.e., including the omitted inventors), executed in three parts (a) inventors BOCK and BEREZIN, (b) inventor SOROKA, and (c) inventors KASPER and KASTRUP)
- (3) a supplemental declaration by inventor SOROKA that corrects an error in his citizenship as stated in (2);
- (4) the processing fee of \$130.00

USSN - 10/574,084

- (5) a Consent of Assignee executed by the assignee ENKAM PHARMACEUTICALS A/S (with attached assignments from the inventors, one from the originally named inventors and the other from the omitted inventors).
- (6) a supplemental ADS supplying the address information for the omitted inventors.

Please charge any deficiency in the fee, or credit any overpayment, to deposit account 02-4035.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.  
Attorneys for Applicant

By: 

David P. Cooper  
Reg. No. 28,005

624 Ninth Street, N.W.  
Washington, D.C. 20001  
Telephone: (202) 628-5197  
Facsimile: (202) 737-3528  
IPC:lms  
G:\ipc\g-i\hoib\BOCK9\pto req correctinventorship.wpd

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	Art Unit:
	)	
BOCK, et al.	)	Examiner:
	)	
Serial No.: 10/574,084	)	Washington, D.C.
	)	
Filed: March 30, 2006	)	
	)	
For: A METHOD OF MODULATING	)	Docket No.: BOCK=9
CELL SURVIVAL,	)	
DIFFERENTIATION AND/OR...	)	Confirmation No.: 3782

STATEMENT (1/2) OF OMITTED INVENTOR IN SUPPORT OF  
REQUEST UNDER 37 CFR 1.48(a)

U.S. Patent and Trademark Office  
Customer Service Window  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

S i r :

I, Christina Kasper, hereby declare

1. Upon information and belief, the above-identified application was filed, and a 37 CFR 1.63 declaration filed, without identifying me as a joint inventor.

2. I should have been identified as a joint inventor with respect to the subject matter of at least one of the claims.

3. The error in inventorship occurred without any deceptive intention on my part.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may

USPN - 10/574,084

jeopardize the validity of the application or any patent issued thereon.

  
Christina Kasper  
(signed)

4/10-2010  
Date

G:\ip\g-1\hob\BCK9\pte kasper statement.wpd

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	Art Unit:
BOCK, et al.	)	Examiner:
Serial No.: 10/574,084	)	Washington, D.C.
Filed: March 30, 2006	)	
For: A METHOD OF MODULATING	)	Docket No.: BOCK=9
CELL SURVIVAL,	)	
DIFFERENTIATION AND/OR...	)	Confirmation No.: 3782

STATEMENT (2/2) OF OMITTED INVENTOR IN SUPPORT OF  
REQUEST UNDER 37 CFR 1.48(a)

U.S. Patent and Trademark Office  
Customer Service Window  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

S i r :

I, Jette Sandholm Jensen Kastrup, hereby declare

1. Upon information and belief, the above-identified application was filed, and a 37 CFR 1.63 declaration filed, without identifying me as a joint inventor.

2. I should have been identified as a joint inventor with respect to the subject matter of at least one of the claims.

3. The error in inventorship occurred without any deceptive intention on my part.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may

USSN - 10/574,084

jeopardize the validity of the application or any patent issued  
thereon.

  
\_\_\_\_\_  
Jette Sandholm Jensen Kastrup  
(signed)

12/10-2010  
Date

G:\ipc\g-1\bois\BCK9\pro kastrup statement.wpd



An Application Data Sheet was filed in reference to this application on March 30, 2006, and a supplemental or substitute ADS will be filed herewith.

Page 1 of 2 Pages

[ ] Original [X] Substitute [ ] Supplemental

Atty Docket: BOCK-9

**COMBINED DECLARATION (37 CFR 1.63) AND POWER OF ATTORNEY FOR  
UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET  
(37 CFR 1.76)**

TITLE OF THE INVENTION	A METHOD OF MODULATING CELL SURVIVAL, DIFFERENTIATION AND/OR SYNAPTIC PLASTICITY
<p>This declaration is directed to:</p> <p>[ ] the attached application;</p> <p>[ ] the application filed in the United States under 35 U.S.C. §111 on _____, as U.S. Appl. No. _____, or</p> <p>[X] the application which was/will be filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an international (PCT) application, <u>PCT/DK2004/000659</u>, filed September 29, 2004, entry requested on March 30, 2006; national stage application received U.S. Appl. No. 10/574,084; §371/§102(e) date <u>May 15, 2007</u> (* if known)</p> <p>[ ] as amended on _____ (if applicable).</p>	
<p>I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;</p>	
<p>I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;</p>	
<p>I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.55, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.</p>	
<p>All statements made herein of my/own knowledge are true; all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.</p>	
<p>As a named inventor, I hereby appoint the following registered practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:</p>	
<p align="center">All of the practitioners associated with Customer Number 001444</p>	
<p>Direct all correspondence to the address associated with Customer Number 001444, which is presently:</p>	
<p align="center"><b>BROWDY AND NEWMARK, P.L.L.C.</b> 624 Ninth Street, N.W. Washington, D.C. 20001-5303 (202) 618-5197</p>	
<p>The undersigned hereby authorizes the U.S. Attorneys or Agents appointed herein to accept and follow instructions from <u>HOIBERG A/S</u> as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. Attorneys or Agents and the undersigned. In the event of a change of the persons from whom instructions may be taken, the U.S. Attorneys or Agents appointed herein will be so notified by the undersigned.</p>	
<p><b>FULL NAME OF INVENTOR(S)</b></p>	
<p>Inventor one: <u>Elisabeth BOCK</u></p> <p>Signature: <u></u></p>	<p>Date: <u>20/9-2006</u></p> <p>Citizen of: <u>Denmark</u></p>
<p>Inventor two: <u>Vladimir BEREZIN</u></p> <p>Signature: <u></u></p>	<p>Date: <u>20.09.2006</u></p> <p>Citizen of: <u>Denmark</u></p>

Page 2 of 2 Pages

Atty. Docket: BOCK-9

Title: A METHOD OF MODULATING CELL SURVIVAL, DIFFERENTIATION AND/OR SYNAPTIC PLASTICITYU.S. Application filed May 15, 2007, Serial No. 10/574,084PCT Application filed September 29, 2004, Serial No. PCT/DK2004/000659

Inventor three: <u>Vladyslav SOROKA</u>	Date: _____
Signature: _____	Citizen of: <u>Ukraine</u>
Inventor four: <u>Christina Kasper</u>	Date: _____
Signature: _____	Citizen of: <u>Denmark</u>
Inventor five: <u>Jette Sandholm Jensen Kastrop</u>	Date: _____
Signature: _____	Citizen of: <u>Denmark</u>
<input type="checkbox"/> Additional inventors or a legal representative are being named on _____ additional form(s) attached hereto.	
<p>All inventors must review application and declaration before signing. All alterations must be initialed and dated by all inventors prior to execution. No alterations can be made after the declaration is signed. All pages of the declaration must be seen by all inventors.</p> <p>Resolving conflicts between Application Data Sheets and Declaration occurs as follows: (1) normally, the latest submitted information governs; (2) if an Application Data Sheet and a declaration are filed the same day, the Application Data Sheet governs, except with respect to the naming of inventors and the identification of their citizenship. See 37 CFR 1.76(d).</p>	



An Application Data Sheet was filed in reference to this application on March 30, 2006, and a supplemental or substitute ADS will be filed herewith.

Page 1 of 2 Pages

[ ] Original [X] Substitute [ ] Supplemental

Atty. Docket: BOCK-9

**COMBINED DECLARATION (37 CFR 1.63) AND POWER OF ATTORNEY FOR  
UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET  
(37 CFR 1.76)**

TITLE OF THE INVENTION	A METHOD OF MODULATING CELL SURVIVAL, DIFFERENTIATION AND/OR SYNAPTIC PLASTICITY
<p>This declaration is directed to:</p> <p>[ ] the attached application;</p> <p>[ ] the application filed in the United States under 35 U.S.C. §111 on _____, as U.S. Appl. No. _____*; or</p> <p>[X] the application which was/will be filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an international (PCT) application, <u>PCT/DK2004/000659</u>, filed September 29, 2004, entry requested on March 30, 2006; national stage application received U.S. Appl. No. 10/574,084; §371/§102(e) date <u>May 15, 2007</u> (* if known)</p> <p>[ ] as amended on _____ (if applicable).</p> <p>I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;</p> <p>I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;</p> <p>I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.</p> <p>All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.</p> <p>As a named inventor, I hereby appoint the following registered practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:</p> <p align="center">All of the practitioners associated with Customer Number 001444</p> <p>Direct all correspondence to the address associated with Customer Number 001444, which is presently:</p> <p align="center">BROWDY AND NEIMARK, P.L.L.C. 624 Ninth Street, N.W. Washington, D.C. 20001-5303 (202) 628-5197</p> <p>The undersigned hereby authorizes the U.S. Attorneys or Agents appointed herein to accept and follow instructions from <u>HOIBERG A/S</u> as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. Attorneys or Agents and the undersigned. In the event of a change of the persons from whom instructions may be taken, the U.S. Attorneys or Agents appointed herein will be so notified by the undersigned.</p>	
FULL NAME OF INVENTOR(S)	
Inventor one: <u>Ellisabeth BOCK</u>	Date: _____
Signature: _____	Citizen of: <u>Denmark</u>
Inventor two: <u>Vladimir BEREZIN</u>	Date: _____
Signature: _____	Citizen of: <u>Denmark</u>

Page 2 of 2 Pages

Atty. Docket: BOCK=9

Title: A METHOD OF MODULATING CELL SURVIVAL DIFFERENTIATION AND/OR SYNAPTIC PLASTICITYU.S. Application filed May 15, 2007, Serial No. 10/574,084PCT Application filed September 29, 2004, Serial No. PCT/DK2004/000659

Inventor three: <u>Vladyslav SOROKA</u>	Date: <u>24.09.2010</u>
Signature: <u>Vladyslav Soroka</u>	Citizen of: <u>Ukraine, Denmark</u>
Inventor four: <u>Christina Kasper</u>	Date: _____
Signature: _____	Citizen of: <u>Denmark</u>
Inventor five: <u>Jette Sandholm Jensen Kastrup</u>	Date: _____
Signature: _____	Citizen of: <u>Denmark</u>
<input type="checkbox"/> Additional inventors or a legal representative are being named on _____ additional form(s) attached hereto.	
<p>All inventors must review application and declaration before signing. All alterations must be initialed and dated by all inventors prior to execution. No alterations can be made after the declaration is signed. All pages of the declaration must be seen by all inventors.</p> <p>Resolving conflicts between Application Data Sheets and Declaration occurs as follows: (1) normally, the latest submitted information governs, (2) if an Application Data Sheet and a declaration are filed the same day, the Application Data Sheet governs, except with respect to the naming of inventors and the identification of their citizenship. See 37 CFR 1.76(d).</p>	

An Application Data Sheet was filed in reference to this application on March 30, 2006, and a supplemental or substitute ADS will be filed herewith.

Page 1 of 2 Pages

☐ Original ☒ Substitute ☐ Supplemental

Atty. Docket: BOCK=9

**COMBINED DECLARATION (37 CFR 1.63) AND POWER OF ATTORNEY FOR  
UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET  
(37 CFR 1.76)**

TITLE OF THE INVENTION	A METHOD OF MODULATING CELL SURVIVAL, DIFFERENTIATION AND/OR SYNAPTIC PLASTICITY
<p>This declaration is directed to:</p> <p><input type="checkbox"/> the attached application;</p> <p><input type="checkbox"/> the application filed in the United States under 35 U.S.C. §111 on _____, as U.S. Appin. No. _____; or</p> <p><input checked="" type="checkbox"/> the application which was/will be filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an international (PCT) application, PCT/DK2004/000659; filed September 29, 2004, entry requested on March 30, 2006; national stage application received U.S. Appin. No. 10/574,084; §371/§102(e) date <u>May 15, 2007</u> * (* if known)</p> <p><input type="checkbox"/> as amended on _____ (if applicable).</p>	
<p>I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;</p>	
<p>I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;</p>	
<p>I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.</p>	
<p>All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.</p>	
<p>As a named inventor, I hereby appoint the following registered practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:</p>	
<p align="center">All of the practitioners associated with Customer Number 001444</p>	
<p>Direct all correspondence to the address associated with Customer Number 001444, which is presently:</p>	
<p align="center">BROWDY AND NEIMARK, P.L.L.C. 624 Ninth Street, N.W. Washington, D.C. 20001-5303 (202) 628-5197</p>	
<p>The undersigned hereby authorizes the U.S. Attorneys or Agents appointed herein to accept and follow instructions from <u>HOIBERG A/S</u> as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. Attorneys or Agents and the undersigned. In the event of a change of the persons from whom instructions may be taken, the U.S. Attorneys or Agents appointed herein will be so notified by the undersigned.</p>	
<p><b>FULL NAME OF INVENTOR(S)</b></p>	
<p>Inventor one: <u>Eliabeth BOCK</u></p> <p>Signature: _____</p>	<p>Date: _____</p> <p>Citizen of: <u>Denmark</u></p>
<p>Inventor two: <u>Vladimir BEREZIN</u></p> <p>Signature: _____</p>	<p>Date: _____</p> <p>Citizen of: <u>Denmark</u></p>

Page 2 of 2 Pages

Atty. Docket: BOCK-9

Title: A METHOD OF MODULATING CELL SURVIVAL, DIFFERENTIATION AND/OR SYNAPTIC PLASTICITYU.S. Application filed May 15, 2007, Serial No. 10/574,084PCT Application filed September 29, 2004, Serial No. PCT/DK2004/000659

Inventor three: <u>Vladyslav SOROKA</u>	Date: _____
Signature: _____	Citizen of: <u>Ukraine</u>
Inventor four: <u>Christina Kasper</u>	Date: <u>4/10-2010</u>
Signature: <u>Christina Kasper</u>	Citizen of: <u>Denmark</u>
Inventor five: <u>Jette Sandholm Jensen Kastrop</u>	Date: <u>12/10-2010</u>
Signature: <u>Jette Sandholm Jensen Kastrop</u>	Citizen of: <u>Denmark</u>
<input type="checkbox"/> Additional inventors or a legal representative are being named on _____ additional form(s) attached hereto.	
<p>All inventors must review application and declaration before signing. All alterations must be initialed and dated by all inventors prior to execution. No alterations can be made after the declaration is signed. All pages of the declaration must be seen by all inventors.</p> <p>Resolving conflict between Application Data Sheets and Declaration occurs as follows: (1) normally, the latest submitted information governs, (2) if an Application Data Sheet and a declaration are filed the same day, the Application Data Sheet governs, except with respect to the naming of inventors and the identification of their citizenship. See 37 CFR 1.76(d).</p>	

**SUPPLEMENTAL DECLARATION (37 CFR 1.63)**

TITLE OF THE INVENTION	A METHOD OF MODULATING CELL SURVIVAL, DIFFERENTIATION AND/OR SYNAPTIC PLASTICITY
<p>This declaration is directed to:</p> <p><input type="checkbox"/> the attached application;</p> <p><input type="checkbox"/> the application filed in the United States under 35 U.S.C. §111 on _____, as U.S. Appl. No. _____*, or</p> <p><input checked="" type="checkbox"/> the application which was/will be filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an international (PCT) application, <u>PCT/DK2004/000659</u>; filed September 29, 2004, entry requested on March 30, 2006; national stage application received U.S. Appl. No. 10/574,084; §371/§102(e) date <u>May 15, 2007</u> (* if known)</p> <p><input type="checkbox"/> as amended on _____ (if applicable).</p> <p>The original and first inventor(s) of the subject matter which is claimed and for which a patent is sought are as follows:</p> <p><u>Elisabeth BOCK</u></p> <p><u>Vladimir BEREZIN</u></p> <p><u>Vladyslav SOROKA</u></p> <p><u>Christina KASPER</u></p> <p><u>Jette Sandholm Jensen KASTRUP</u></p> <p>The purpose of this Supplemental Declaration is to correct an error in the identification of the citizenship of inventor SOROKA. Pursuant to MPEP 603, Example 1, it is executed by SOROKA alone. The correct citizenship for inventor SOROKA is indicated below.</p>	
<b><u>SUPPLEMENTAL DECLARATION EXECUTED BY:</u></b>	
Inventor three: <u>Vladyslav SOROKA</u>	Date: <u>26.10.2010</u>
Signature: <u><i>Vladyslav Soroka</i></u>	Citizen of: <u>Denmark</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	Art Unit:
	)	
BOCK, et al.	)	Examiner:
	)	
Serial No.: 10/574,084	)	Washington, D.C.
	)	
Filed: March 30, 2006	)	
	)	
For: A METHOD OF MODULATING	)	Docket No.: BOCK=9
CELL SURVIVAL,	)	
DIFFERENTIATION AND/OR...	)	Confirmation No.: 3782

CONSENT OF ASSIGNEE IN SUPPORT OF REQUEST  
TO CORRECT INVENTORSHIP UNDER 1.48(a)

S i r :

37 CFR 1.48(a) says that if an assignment has been executed by any of the originally named inventors, a consent of assignee is required for correction of inventorship.

1. The Assignee(s) of this application is/are ENKAM PHARMACEUTICALS A/S. The following statement is made to comply with 37 CFR §3.73(b):

The interest of each Assignee is evidenced by

1A. ☐ An assignment from \_\_\_\_\_  
to \_\_\_\_\_ recorded by the USPTO on \_\_\_\_\_ at reel  
\_\_\_\_\_, frame \_\_\_\_\_; [repeat as needed for multiple  
assignments]

1B. ☒ The enclosed documentary evidence of the chain of equitable or legal title from the original owner to Petitioner: (1) Assignment from originally named inventors to the above-identified assignee; (2) assignment from the previously omitted inventor(s) to the above-identified assignee.

The documents evidencing the ownership and chain of title of the instant patent or application have been reviewed and to the best of each Assignee(s) knowledge and belief, title is in Assignee(s) as above stated.

2. The aforementioned records establish the right of the Assignee(s) to take action. See 37 CFR 3.73(b)(1)(i).

3. In accordance with 3.73(c)(2), it is stated ☒ that the


USSN - 10/574,084

aforestated assignee owns the entire interest [ ] that the aforestated assignees each own a \_\_\_\_% interest in the above-identified application.

5. This assignee hereby consents to a request to [X] add Christina Kasper and Jette Sandholm Jensen Kastrup as inventor(s), [ ] delete \_\_\_\_\_ as inventor(s), pursuant to 37 CFR 1.48(a).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FOR ASSIGNEE: Enkam Pharmaceuticals A/S

  
\_\_\_\_\_  
(signed) 78/SEP/2010 (date)  
MORTEN ALBRECHTSEN (typed)  
CEO (title)

624 Ninth Street, N.W.  
Washington, D.C. 20001  
Telephone: (202) 628-5197  
Facsimile: (202) 737-3528  
IPC:lms  
G:\ipc\g-1\hoib\DOCK9\pto consentassignee.wpd

RECEIVED

Assignment of Invention

09 MAY 2007

Page 1 of 6

Attorney Docket: BOCK9

HØIBERG

UTS

Title: A METHOD OF MODULATING CELL SURVIVAL, DIFFERENTIATION  
AND/OR SYNAPTIC PLASTICITY

WORLDWIDE ASSIGNMENT FROM INDIVIDUALS

WHEREAS I own all or part of an invention whose present  
title is that set forth above,

for which patent applications have been

( ) drafted and attached hereto

( ) executed on even date herewith<sup>1</sup>,

( XX ) filed as set forth below:

Denmark PA 2003 01418 September 30, 2003

All PCT States PCT/DK2004/000659 September 29, 2004

[XX] (which PCT application entered the U.S. national stage as  
Ser. No. 10/574,084)

AND WHEREAS ENKAM PHARMACEUTICALS A/S of Fruebjergvej 3, DK-2100  
Copenhagen Ø, Denmark (hereinafter ASSIGNEE) is interested in  
acquiring the entirety of my right, title and interest in said  
invention, and related patents and applications, **worldwide**:

NOW THEREFORE IT IS AGREED BETWEEN MYSELF AND ASSIGNEE THAT:

1. Definitions:

1.1. ASSIGNED APPLICATIONS hereby means (a) any executed or  
filed application identified above (including any national or  
regional stage, identified or not, of an identified PCT  
application), or any draft application attached hereto, or any  
executed or filed application which discloses and claims an

---

<sup>1</sup> Use this box only if §1.63 declaration executed the  
same day.



Attorney Docket: BOCK9

Title: A METHOD OF MODULATING CELL SURVIVAL, DIFFERENTIATION  
AND/OR SYNAPTIC PLASTICITY

invention disclosed in such a draft application; (b) any application filed in the U.S. (provisional or nonprovisional), a foreign country, or under an international treaty (e.g., PCT), from which an application of (a) above directly or indirectly claims the benefit, under the Paris Convention or under U.S. (e.g., 35 USC 120 or 119(e)) or foreign law; and (c) any application, filed in the U.S., a foreign country, or under an international treaty (including PCT), which directly or indirectly claims the benefit, under the Paris Convention or under U.S. or foreign law, of an application of (a) or (b) above, including without limitation any continuation, division, or continuation-in-part applications, or a U.S. nonprovisional application (which may be a PCT application designating the U.S.) which claims 35 USC 119(e) benefit from a prior U.S. provisional application. The reference above to a PCT (international) application is intended to include the national or regional stage applications derived therefrom. Applications include both applications for patents and applications for other forms of protection for inventions, such as inventors' certificates.

1.2. ASSIGNED PATENTS hereby means any U.S. or foreign patent identified above, or which has issued or hereafter issues on an ASSIGNED APPLICATION, including any reissues, reexaminations, renewals or extensions of such patents; and any other form of protection for the inventions disclosed therein, such as an inventors' certificate, which may be granted in the U.S. or a foreign country (or group of countries).

1.3. ASSIGNED INVENTIONS hereby means any invention, to which I made an inventive contribution, which was disclosed in an ASSIGNED APPLICATION or an ASSIGNED PATENT, whether or not such invention was claimed, and whether or not such invention was conceived or made at the time of execution of this assignment.

Attorney Docket: BOCK9

Title: A METHOD OF MODULATING CELL SURVIVAL, DIFFERENTIATION  
AND/OR SYNAPTIC PLASTICITY

2. Assignment

I hereby assign all of my right, title and interest in the ASSIGNED INVENTIONS, the ASSIGNED APPLICATIONS, and the ASSIGNED PATENTS, and any right to assert domestic or foreign priority from the ASSIGNED APPLICATIONS, to ASSIGNEE. In the case of CIPs, this assignment includes inventions first disclosed in said CIP.

3. Cooperation with Prosecution

I agree to execute, whenever requested by ASSIGNEE or its legal representatives, all lawful patent applications, assignments, declarations, disclaimers, and other papers, and to carry out such other lawful acts, which ASSIGNEE or its legal representatives may deem necessary or desirable for securing or maintaining said patents or other forms of protection or for establishing ASSIGNEE's title therein; to provide ASSIGNEE or its legal representatives with such executed papers, and with all pertinent facts and documents relating to said application as may be known or reasonably accessible to me; and to testify on behalf of ASSIGNEE in any legal proceeding related thereto; all without further compensation to me (except for compensation of reasonably incurred out-of-pocket expenses); and all in an expeditious and conscientious manner.

I also agree that I will not testify in a legal proceeding relating to said patents or applications on behalf of another party, or otherwise assist another party in connection with such a legal proceeding or in connection with any evaluation of the patentability, validity or scope of said patents and applications, without the prior written consent of ASSIGNEE or its legal representatives, if such consent can be lawfully required by ASSIGNEE.

Attorney Docket: BOCK9

Title: A METHOD OF MODULATING CELL SURVIVAL, DIFFERENTIATION  
AND/OR SYNAPTIC PLASTICITY

Nothing herein should be construed to imply an obligation on my part to satisfy expenses of prosecuting and maintaining any ASSIGNED APPLICATION or ASSIGNED PATENT.

4. Request for Patent Grant

I hereby authorize and request the patent office officials throughout the world to issue any and all patents or other forms of protection for inventions resulting from the aforesaid applications to ASSIGNEE, as ASSIGNEE of the interest here assigned.

5. Warranty of Title; Acknowledgment of Duty of Disclosure

I hereby covenant and warrant that I possess some right, title and interest in said invention or in one or more of said draft applications, applications, patents or other forms of protection, that I have fully disclosed to ASSIGNEE or its legal representatives, in writing, all encumbrances, clouds or limitations which are or should be known to me which affect my right, title and interest, in the United States or any foreign country, and that I have likewise disclosed to ASSIGNEE or its legal representatives the identity of all other persons, natural or juristic, possessing or claiming to possess some right, title or interest in the foregoing. (If such persons are listed as inventors at the end of this Assignment form, then that constitutes a disclosure of identity.) This duty of disclosure is a continuing one and I will inform ASSIGNEE or its legal representatives of any relevant information which becomes known to me after the execution of this Assignment.

I will, upon ASSIGNEE's request, or that of or its legal representatives, provide information known to or readily ascertainable by me concerning the locations of such persons and

Attorney Docket: BOCK9

Title: A METHOD OF MODULATING CELL SURVIVAL, DIFFERENTIATION  
AND/OR SYNAPTIC PLASTICITY

the circumstances allegedly giving rise to their right, title or interest, such as their alleged inventive contributions.

I hereby covenant and warrant that (except as set forth in an attached written disclosure which is incorporated by reference herein) I have full right to convey the entire interest herein assigned, that I have not executed, and will not execute, any agreement in conflict therewith, and that I have and will comply with the duty of disclosure with respect to said application.

6. Authority to Identify and Correct

I hereby grant Iver P. Cooper, Reg. No. 28,005, and other attorneys of Browdy and Neimark, PLLC (Customer No. 001444) a delegable power to insert on this Assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office or any foreign patent office for recordation of this document, or to make such corrections on this Assignment as I may authorize, or the Assignee may authorize, orally or in writing.

7. Biological Materials; Right of Reference

I assign to ASSIGNEE all of my right, title and interest in any biological materials I have developed, propagated or deposited during the course of employment with ASSIGNEE, or which are referred to in said application, or which may be necessary to enable one to make or use said invention, and agree that ASSIGNEE shall have control over any deposits which I have caused to be made of such biological materials.

I likewise assign to ASSIGNEE my right of reference, for purposes of obtaining regulatory approval, to any data which I have developed during the course of employment with ASSIGNEE, or which are referred to in said application, or which may be necessary to enable one to make or use said invention.

Attorney Docket: BOCK9

Title: A METHOD OF MODULATING CELL SURVIVAL, DIFFERENTIATION  
AND/OR SYNAPTIC PLASTICITY

8. Successors in Interest

The terms and covenants of this assignment shall inure to the benefit of said ASSIGNEE, its heirs, successors, administrators, and assigns, and shall be binding upon my heirs, successors, administrators and assigns.

9. Real Party in Interest

I recognize that this assignment of my rights in this application makes the ASSIGNEE the real party in interest with respect thereto and that the ASSIGNEE's interests will then be represented by the attorney(s) and/or agent(s) appointed by them to the exclusion of any of my personal interests which may conflict therewith. In the event of any dispute which I may have with ASSIGNEE over the subject matter of this assignment, I acknowledge that I will have to retain independent legal counsel with respect thereto at my own expense.

Signature Elisabeth Bock  
Date \_\_\_\_\_ Inventor Elisabeth BOCK

Signature Vladimir Berezin  
Date \_\_\_\_\_ Inventor Vladimir BEREZIN

Signature Vladyslav Soroka  
Date \_\_\_\_\_ Inventor Vladyslav SOROKA

Assignment of Invention

Page 1 of 6

Attorney Docket: BOCK9

Title: A METHOD OF MODULATING CELL SURVIVAL, DIFFERENTIATION  
AND/OR SYNAPTIC PLASTICITY

## WORLDWIDE ASSIGNMENT FROM INDIVIDUALS

WHEREAS I own all or part of an invention whose present  
title is that set forth above,

for which patent applications have been

☐ drafted and attached hereto

☐ executed on even date herewith<sup>1</sup>,

☒ filed as set forth below:

Denmark PA 2003 01418 September 30, 2003

All PCT States PCT/DK2004/000659 September 29, 2004

[XX] (which PCT application entered the U.S. national stage as  
Ser. No. 10/574,084)

AND WHEREAS ENKAM PHARMACEUTICALS A/S of Fruebjergvej 3, DK-2100  
Copenhagen Ø, Denmark (hereinafter ASSIGNEE) is interested in  
acquiring the entirety of my right, title and interest in said  
invention, and related patents and applications, worldwide:

NOW THEREFORE IT IS AGREED BETWEEN MYSELF AND ASSIGNEE THAT:

## 1. Definitions:

1.1. ASSIGNED APPLICATIONS hereby means (a) any executed or  
filed application identified above (including any national or  
regional stage, identified or not, of an identified PCT

---

<sup>1</sup> Use this box only if §1.63 declaration executed the  
same day.

Assignment of Invention

Page 2 of 6

Attorney Docket: BOCK9

Title: A METHOD OF MODULATING CELL SURVIVAL, DIFFERENTIATION  
AND/OR SYNAPTIC PLASTICITY

application), or any draft application attached hereto, or any executed or filed application which discloses and claims an invention disclosed in such a draft application; (b) any application filed in the U.S. (provisional or nonprovisional), a foreign country, or under an international treaty (e.g., PCT), from which an application of (a) above directly or indirectly claims the benefit, under the Paris Convention or under U.S. (e.g., 35 USC 120 or 119(e)) or foreign law; and (c) any application, filed in the U.S., a foreign country, or under an international treaty (including PCT), which directly or indirectly claims the benefit, under the Paris Convention or under U.S. or foreign law, of an application of (a) or (b) above, including without limitation any continuation, division, or continuation-in-part applications, or a U.S. nonprovisional application (which may be a PCT application designating the U.S.) which claims 35 USC 119(e) benefit from a prior U.S. provisional application. The reference above to a PCT (international) application is intended to include the national or regional stage applications derived therefrom. Applications include both applications for patents and applications for other forms of protection for inventions, such as inventors' certificates.

1.2. ASSIGNED PATENTS hereby means any U.S. or foreign patent identified above, or which has issued or hereafter issues on an ASSIGNED APPLICATION, including any reissues, reexaminations, renewals or extensions of such patents; and any other form of protection for the inventions disclosed therein, such as an inventors' certificate, which may be granted in the U.S. or a foreign country (or group of countries).

1.3. ASSIGNED INVENTIONS hereby means any invention, to which I made an inventive contribution, which was disclosed in an

Assignment of Invention

Page 3 of 6

Attorney Docket: BOCK9

Title: A METHOD OF MODULATING CELL SURVIVAL, DIFFERENTIATION  
AND/OR SYNAPTIC PLASTICITY

ASSIGNED APPLICATION or an ASSIGNED PATENT, whether or not such invention was claimed, and whether or not such invention was conceived or made at the time of execution of this assignment.

2. Assignment

I hereby assign all of my right, title and interest in the ASSIGNED INVENTIONS, the ASSIGNED APPLICATIONS, and the ASSIGNED PATENTS, and any right to assert domestic or foreign priority from the ASSIGNED APPLICATIONS, to ASSIGNEE. In the case of CIPs, this assignment includes inventions first disclosed in said CIP.

3. Cooperation with Prosecution

I agree to execute, whenever requested by ASSIGNEE or its legal representatives, all lawful patent applications, assignments, declarations, disclaimers, and other papers, and to carry out such other lawful acts, which ASSIGNEE or its legal representatives may deem necessary or desirable for securing or maintaining said patents or other forms of protection or for establishing ASSIGNEE's title therein; to provide ASSIGNEE or its legal representatives with such executed papers, and with all pertinent facts and documents relating to said application as may be known or reasonably accessible to me; and to testify on behalf of ASSIGNEE in any legal proceeding related thereto; all without further compensation to me (except for compensation of reasonably incurred out-of-pocket expenses); and all in an expeditious and conscientious manner.

I also agree that I will not testify in a legal proceeding relating to said patents or applications on behalf of another party, or otherwise assist another party in connection with such a legal proceeding or in connection with any evaluation of the



Assignment of Invention

Page 4 of 6

Attorney Docket: BOCK9

Title: A METHOD OF MODULATING CELL SURVIVAL, DIFFERENTIATION  
AND/OR SYNAPTIC PLASTICITY

patentability, validity or scope of said patents and applications, without the prior written consent of ASSIGNEE or its legal representatives, if such consent can be lawfully required by ASSIGNEE.

Nothing herein should be construed to imply an obligation on my part to satisfy expenses of prosecuting and maintaining any ASSIGNED APPLICATION or ASSIGNED PATENT.

#### 4. Request for Patent Grant

I hereby authorize and request the patent office officials throughout the world to issue any and all patents or other forms of protection for inventions resulting from the aforesaid applications to ASSIGNEE, as ASSIGNEE of the interest here assigned.

#### 5. Warranty of Title; Acknowledgment of Duty of Disclosure

I hereby covenant and warrant that I possess some right, title and interest in said invention or in one or more of said draft applications, applications, patents or other forms of protection, that I have fully disclosed to ASSIGNEE or its legal representatives, in writing, all encumbrances, clouds or limitations which are or should be known to me which affect my right, title and interest, in the United States or any foreign country, and that I have likewise disclosed to ASSIGNEE or its legal representatives the identity of all other persons, natural or juristic, possessing or claiming to possess some right, title or interest in the foregoing. (If such persons are listed as inventors at the end of this Assignment form, then that constitutes a disclosure of identity.) This duty of disclosure is a continuing one and I will inform ASSIGNEE or its legal

## Assignment of Invention

Page 5 of 6

Attorney Docket: BOCK9

Title: A METHOD OF MODULATING CELL SURVIVAL, DIFFERENTIATION  
AND/OR SYNAPTIC PLASTICITY

representatives of any relevant information which becomes known to me after the execution of this Assignment.

I will, upon ASSIGNEE's request, or that of or its legal representatives, provide information known to or readily ascertainable by me concerning the locations of such persons and the circumstances allegedly giving rise to their right, title or interest, such as their alleged inventive contributions.

I hereby covenant and warrant that (except as set forth in an attached written disclosure which is incorporated by reference herein) I have full right to convey the entire interest herein assigned, that I have not executed, and will not execute, any agreement in conflict therewith, and that I have and will comply with the duty of disclosure with respect to said application.

6. Authority to Identify and Correct

I hereby grant Iver P. Cooper, Reg. No. 28,005, and other attorneys of Browdy and Neimark, PLLC (Customer No. 001444) a delegable power to insert on this Assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office or any foreign patent office for recordation of this document, or to make such corrections on this Assignment as I may authorize, or the Assignee may authorize, orally or in writing.

7. Biological Materials; Right of Reference

I assign to ASSIGNEE all of my right, title and interest in any biological materials I have developed, propagated or deposited during the course of employment with ASSIGNEE, or which are referred to in said application, or which may be necessary to enable one to make or use said invention, and agree that ASSIGNEE

Assignment of Invention

Page 6 of 6

Attorney Docket: BOCK9

Title: A METHOD OF MODULATING CELL SURVIVAL, DIFFERENTIATION  
AND/OR SYNAPTIC PLASTICITY

shall have control over any deposits which I have caused to be made of such biological materials.

I likewise assign to ASSIGNEE my right of reference, for purposes of obtaining regulatory approval, to any data which I have developed during the course of employment with ASSIGNEE, or which are referred to in said application, or which may be necessary to enable one to make or use said invention.

#### 8. Successors in Interest

The terms and covenants of this assignment shall inure to the benefit of said ASSIGNEE, its heirs, successors, administrators, and assigns, and shall be binding upon my heirs, successors, administrators and assigns.

#### 9. Real Party in Interest

I recognize that this assignment of my rights in this application makes the ASSIGNEE the real party in interest with respect thereto and that the ASSIGNEE's interests will then be represented by the attorney(s) and/or agent(s) appointed by them to the exclusion of any of my personal interests which may conflict therewith. In the event of any dispute which I may have with ASSIGNEE over the subject matter of this assignment, I acknowledge that I will have to retain independent legal counsel with respect thereto at my own expense.

Signature



Date

4/10-2010

Inventor Christina Kasper

Signature



Date

12/10-2010

Inventor Jette Sandholm Jensen Kastrup

c:\ipc\5-1\hoib\BOCK9\pto assignment\addedinventors.doc